Key Highlights
- Below Oxurion’s possession, Exagis has developed from an inner eCRF answer right into a broader Scientific Information Administration System (CDMS) serving exterior prospects
- Exagis has already supported greater than 25 scientific initiatives involving over 16,000 sufferers, 600 scientific websites and 18 sponsors
- The platform is now commercializing, individually recognized and priced inside buyer engagements, producing software program revenues
- Exagis is now increasing right into a broader software program ecosystem supporting a number of levels of the scientific growth course of
- Every new research, buyer and acquisition contributes operational experience, workflows and proprietary metadata that repeatedly strengthen the platform
- Exagis is designed to turn out to be the expertise spine of Oxurion
Leuven, BELGIUM – June 8, 2026 –8:30 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical firm based mostly in Leuven, right this moment introduced the launch of a software-driven progress technique centered on Exagis, its proprietary scientific analysis platform developed inside its subsidiary Axiodis CRO.
Already used throughout greater than 16,000 sufferers, 600 scientific websites and 18 sponsors, Exagis is progressively evolving from an inner operational instrument right into a business software program platform serving the broader scientific growth market.
This initiative represents a key step in Oxurion’s transformation towards a extra scalable and technology-driven enterprise mannequin, combining scientific operations experience, software program growth and proprietary operational knowledge.
From scientific operations to software program
Initially developed to assist scientific trial knowledge assortment, Exagis has progressively developed right into a broader Scientific Information Administration System (CDMS) designed to handle the rising complexity of contemporary scientific research.
Exagis has been constructed and refined by means of years of real-world scientific operations. Since 2017, the platform has supported greater than 25 scientific initiatives involving over 16,000 sufferers, greater than 600 scientific websites and 18 sponsors.
Over latest months, Oxurion has accelerated the commercialization of Exagis as a standalone software program answer. The platform is now individually recognized and priced inside buyer engagements, reflecting its rising strategic significance throughout the Group and producing software program revenues.
Developed by scientific operations professionals for operational customers, Exagis locations a powerful emphasis on usability, regulatory compliance and productiveness. Its design has been formed immediately by the sensible wants and workflows encountered in day-to-day scientific analysis operations.
A platform strengthened by each research
A key differentiating issue of Exagis is its steady publicity to real-world scientific operations by means of Axiodis.
The platform captures and buildings proprietary operational workflows, metadata and course of information generated by means of ongoing research. As new prospects, initiatives and future acquisitions are built-in, Exagis repeatedly accumulates extra operational intelligence that may be leveraged to enhance effectivity, automation and decision-making.
Oxurion’s expertise technique additionally contains the progressive integration of focused synthetic intelligence capabilities centered on sensible operational advantages, together with research design assist, knowledge standardization, quality control and regulatory workflows.
By combining software program, operational experience and proprietary operational knowledge, Oxurion believes Exagis can set up an more and more differentiated and scalable place throughout the scientific analysis expertise ecosystem.
Subsequent Growth Milestone
The following growth milestone for Exagis is the deployment of its first digital Trial Grasp File (eTMF) module, anticipated in July 2026. The module is designed to assist pharmaceutical and biotechnology firms securely handle and manage scientific trial documentation and represents step one in Exagis’ growth right into a broader modular eClinical software program platform.
Future developments are anticipated to incorporate extra capabilities resembling research randomization enhancement, scientific provide administration and superior knowledge administration functionalities.
A central pillar of Oxurion’s progress technique
Exagis is designed to turn out to be the widespread expertise spine of Oxurion’s scientific analysis actions, supporting each present operations and future acquisitions.
Its deployment throughout the Group is anticipated to facilitate operational standardization, speed up integration and create rising synergies between software program and companies.
By progressively increasing the function of Exagis inside its enterprise mannequin, Oxurion goals to extend the contribution of technology-driven revenues whereas strengthening the long-term strategic worth of its software program ecosystem.
About Oxurion
Oxurion is constructing a technology-enabled scientific analysis and software program platform. The Firm combines scientific operations experience, software program innovation and proprietary operational knowledge to assist pharmaceutical, biotechnology and medical machine sponsors. Extra info is on the market at www.oxurion.com.
Necessary details about forward-looking statements
Sure statements on this press launch could also be thought of “forward-looking”. Such forward-looking statements are based mostly on present expectations, and, accordingly, entail and are influenced by varied dangers and uncertainties. The Firm due to this fact can not present any assurance that such forward-looking statements will materialize and doesn’t assume any obligation to replace or revise any forward-looking assertion, whether or not on account of new info, future occasions, or every other purpose. Further info regarding dangers and uncertainties affecting the enterprise and different elements that would trigger precise outcomes to vary materially from any ahead wanting assertion is contained within the Firm’s Annual Report. This press launch doesn’t represent a proposal or invitation for the sale or buy of securities or property of Oxurion in any jurisdiction. No securities of Oxurion could also be provided or bought inside the US with out registration beneath the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any relevant U.S. state securities legal guidelines.
For additional info please contact: